Connect with us

Emerging Markets

Green Globe International Inc (OTCMKTS: GGII) Breakout Out Northbound as Spinoff Hempacco HPCO Set to IPO on Nasdaq

Published

on

Green Globe International Inc (OTCMKTS: GGII) is rocketing up the charts out of sub penny land as the Company’s Nasdaq spinoff Hempacco set to IPO later this week. HPCO will IPO on the Nasdaq and expects to raise up to $6 million at about $6 per share. Hempacco is a vertically integrated Hemp manufacturing company in San Diego, California operating out of a 53,000 square foot state of the art Manufacuring facility. It owns The Real Stuff™ Hemp Cigarettes CBD Smokabls, offers hemp cigarettes as a private label supplier and owns its own CBD and Hemp vending machines to roll out product around the country. Besides owning and manufacturing its own name brand, Hempacco also provides private label hemp cigarette full-service product development, manufacturing, and logistics, and CBD automated retail concepts with vending machines. Hempacco’s mission is to be the most recognized name brand of Hemp Smokable products in the world.  

GGII is under heavy accumulation and currently rocketing up the charts and its easy to see why; this is a Company with a lot going for it, besides the HPCO Nasdaq IPO in which GGII is the majority shareholder, fueled by Hempacco financials that have produced higher topline revenue from a tiny base, positive gross profit, variable gross margin, increased operating losses but reduced negative operating margin and growing cash used in operations, GGII has a long history of explosive moves syrocketing from current levels to well over $0.16 per share in Spring of 2021 and investors are hoping the stock can do it again. The Companys subsidiary HempBox-GGII recently partnered with High Street CBD to roll out CBD vending machines with an educational twist – expanding consumer knowledge and the benefits of CBD products and increasing ease of accessibility. Also, Green Star Labs, Inc., a fifty-percent owned GGII entity, is developing and manufacturing its own line of cannabinoid, nutraceuticals, and beauty care products for convenience stores and smoke shops.  

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Green Globe International Inc (OTCMKTS: GGII) through its wholly owned subsidiary Hempacco Co, Inc. is Disrupting Tobacco. Nearly $1 Trillion industry with herb and hemp-based alternatives to nicotine cigarettes by manufacturing and marketing consumer goods, including CBG and CBD Hemp cigarettes. The Company owns and licenses intellectual property, has conducted extensive research and development, and is engaged in manufacturing and sales of smokable Hemp brands, including The Real Stuff Hemp Smokables. The Hempacco Co., Inc. operating segments include joint-venture private label agreements and sales, Intellectual Property licensing, and the development and sales of in-house brands using patented counter displays as well as six hundred Kiosk vending machines called HempBoxes.  

Hempacco is a vertically integrated Hemp manufacturing company in San Diego, California operating out of a 53,000 square foot state of the art Manufacuring facility. It owns The Real Stuff™ Hemp Cigarettes CBD Smokables, offers hemp cigarettes as a private label supplier and owns its own CBD and Hemp vending machines to roll out product around the country. Besides owning and manufacturing its own name brand, Hempacco also provides private label hemp cigarette full-service product development, manufacturing, and logistics, and CBD automated retail concepts with vending machines. Hempacco’s mission is to be the most recognized name brand of Hemp Smokable products in the world. Hempacco is already the largest producer of Hemp Cigarettes in the continent, and with integrated end to end warehousing and logistics, Hemp Cigarette brands can warehouse their raw material or finished goods in a dry, refrigerated, or frozen warehouse in the 53,000 square foot plant in San Diego. Hempaco is reportedly doing about $4 million in annual revenues and holds over $10 million in assets.  

https://twitter.com/DarULQalb/status/1562496834916220930

To Find out the inside Scoop on GGII Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GGII

Microcapdaily first covered GGII on April 26, 2021 when the stock was in the $0.02 range stating at the time: “Green Globe International Inc (OTCMKTS: GGII) is heating up in recent trading with large 6- and 7-digit buys coming in and Monday’s volume topping $20 million in dollar volume on 1.2 billion shares traded. GGII has emerged in recent months as an investor favorite and is currently among the most actively searched and talked about stocks in small caps. Currently under heavy accumulation GGII is looking to blaze a path along the likes of Enzolytics or Tesoro and break out into a whole new dimension – Tesoro went to multi dollars – a break over $0.026 and its blue skies ahead.”  

Green Globe International Inc (OTCMKTS: GGII) and its subsidiaries develop, manufacture, market, and sell consumer goods, including herb and hemp smokables rolling paper. It trades on the OTC under the ticker GGII. Green Globe and its subsidiaries current projects include: 

  1. Herb and Cannabinoid Cigarettes, including CBD Cigarettes  
  2. Manufacturing hemp rolling papers called hemp blunts 
  3. CBD, nutritional supplements, and beauty care products 
  4. Online sales of CBD products  
  5. Joint Ventures with large distributors and celebrities like Rick Ross and Cheech & Chong  
  6. The Real Stuff brand of hemp smokables  

Green Globe (GGII) owns or has interests in several brands and companies including; Green Star Labs, Inc., changing how people feel about themselves inside and out with nutritional supplements, CBD, and beauty products, and hemp CBD cigarette and rolling paper manufacturer Hempacco Co. Inc., Disrupting Tobacco’s™ $1 Trillion tobacco industry, with its subsidiaries and joint ventures including HempBox Vending, Inc. vending and advertising company, Cali Vibes, Inc. Cannabinoid cigarettes, HempHop Smokables, Inc., partnering with music producer and rapper Rick Ross, Cheech and Chong Smokables, Inc. delivers cannabinoid Hemp CBD cigarettes to consumers with Cheech and Chong as partners. The Real Stuff Smokables, Inc. 

Earlier this year GGII announced Green Star Labs, Inc., a fifty-percent owned GGII entity, is developing and manufacturing its own line of cannabinoid, nutraceuticals, and beauty care products for convenience stores and smoke shops. The new product line, called The Real Stuff, will debut at the ASD Market Week show in Las Vegas in February and includes CBD oils, CBD roll-ons, CBD tinctures, CBD capsules, CBD gummies, and CBD creams, among others. 

The Real Stuff Product Line Highlights: 

  • A new line of nutraceuticals for convenience stores nationwide 
  • Small pocket-size CBD roll-ons 
  • Impulse buy products starting at $9.99 
  • Regular size tinctures for repeat customers 
  • Counter displays that sit next to the cash register 

“We can now work from concept to a finished CBD or nutraceutical product in the same building,” said Jorge Olson, CMO of GGII. “We’re looking for more white-label partnerships and working on developing more of our brands,” concluded Mr. Jorge Olson. 

https://twitter.com/SalsTradingOTC/status/1562823482886348802

For More on GGII Subscribe Right Now!

Currently trading at a $124 million market valuation GGII is rocketing up the charts out of sub penny land as the Company’s Nasdaq spinoff Hempacco set to IPO later this week. HPCO will IPO on the Nasdaq and expects to raise up to $6 million at about $6 per share. Hempacco is a vertically integrated Hemp manufacturing company in San Diego, California operating out of a 53,000 square foot state of the art Manufacuring facility. It owns The Real Stuff™ Hemp Cigarettes CBD Smokables, offers hemp cigarettes as a private label supplier and owns its own CBD and Hemp vending machines to roll out product around the country. Besides owning and manufacturing its own name brand, Hempacco also provides private label hemp cigarette full-service product development, manufacturing, and logistics, and CBD automated retail concepts with vending machines. Hempacco’s mission is to be the most recognized name brand of Hemp Smokable products in the world. GGII is under heavy accumulation and currently rocketing up the charts and it’s easy to see why; this is a Company with a lot going for it, besides the HPCO Nasdaq IPO in which GGII is the majority shareholder, fueled by Hempacco financials that have produced higher topline revenue from a tiny base, positive gross profit, variable gross margin, increased operating losses but reduced negative operating margin and growing cash used in operations, GGII has a long history of explosive moves skyrocketing from current levels to well over $0.16 per share in Spring of 2021 and investors are hoping the stock can do it again. The Companys subsidiary HempBox-GGII recently partnered with High Street CBD to roll out CBD vending machines with an educational twist – expanding consumer knowledge and the benefits of CBD products and increasing ease of accessibility. Also, Green Star Labs, Inc., a fifty-percent owned GGII entity, is developing and manufacturing its own line of cannabinoid, nutraceuticals, and beauty care products for convenience stores and smoke shops. We will be updating on GGII when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with GGII.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in GGII either long or short and we have not been compensated for this article.

Emerging Markets

Strong Financials and Social Media Buzz Propel Forza X1, Inc. (NASDAQ:FRZA) to New Heights

Published

on

Forza X1, Inc. (Nasdaq: FRZA) shares witnessed an exceptional and unforeseen surge in its share price, skyrocketing by 151% early morning of June 5th, 2023.

Forza X1, Inc. (Nasdaq: FRZA) shares witnessed an exceptional and unforeseen surge in its share price, skyrocketing by 151% early morning of June 5th, 2023. This surge was accompanied by an unprecedented level of trading volume, marking a significant departure from the previously observed average. Notably, the stock’s trading volume had been relatively low in recent months, with numerous days experiencing trading activity of less than 1,000 shares. Without any apparent news or filings, the cause behind this sudden surge remains a subject of intrigue and speculation among market participants.

What happened?

Firstly it’s important to note that $FRZA is a spin-off of Twin Vee PowerCats Co. (Nasdaq: VEEE). $VEEE is the parent company handling the design, manufacturing, and distribution of recreational and commercial, off-shore power catamaran boats while $FRZA is the new developer of electric sport boats with a mission to accelerate the adoption of sustainable recreational boating.

To Discover the Inside Scoop on FRZA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Upon examination of the company, no discernible filings or press releases have been identified to account for today’s remarkable shift. However, it seems that a tweet disseminated by the company caught the attention of retail investors, subsequently generating an enormous surge in trading volume.

This recent occurrence serves as yet another compelling demonstration of the significant impact that the retail community can exert when armed with information regarding a small float micro-cap stock, particularly when the conditions align favorably and validate the potential for substantial gains. The tweet, skillfully crafted by the company’s social media team, featured a compelling GIF and clever “Don’t miss the boat” blurb, demonstrating a keen understanding of their business’s essence. 

The timely and engaging content proved to be a perfect execution, capturing the attention and imagination of investors in a manner that resonated deeply with the nature of the company’s operations.

Overview of Twin Vee PowerCats Co. Financials

Could the surge in share price also reflect the market’s enthusiastic response to Twin Vee’s strong financial results for the first quarter of 2023? 

On May 15, 2023, Twin Vee PowerCats Co. released its financials demonstrating a substantial increase in net revenue and notable improvements in the gas-powered boat segment.

https://twitter.com/JohnZidar/status/1665685698400141313?s=20

Twin Vee PowerCats Co. (Nasdaq: VEEE) reported strong financial results for the first quarter ended March 31, 2023. The company experienced a notable 51% increase in net revenue, reaching $8.9 million compared to $5.9 million in the same period last year. The gas-powered boat segment achieved a net income of $181,000, significantly improving from the net loss of $626,000 in Q1 2022.

However, as per GAAP accounting policy, Twin Vee’s consolidated financial statements resulted in a total net loss of $1.8 million for the quarter, primarily due to their majority ownership in Forza X1, Inc. (Nasdaq: FRZA), an electric boat company. Twin Vee reported cash, cash equivalents, restricted cash, and marketable securities of approximately $12.6 million as of March 31, 2023.

The company has been expanding its product lineup, including introducing the Aquasport mono-hull boat brand. Twin Vee is confident these efforts will contribute to business scalability and brand growth. They aim to optimize inventory levels and production costs while closely monitoring market conditions, dealer inventories, and economic indicators.

Financial highlights for Q1 2023

  • Total revenue: $8,877,000 (51% increase compared to Q1 2022)
  • Gross profit: $3,222,000
  • Net income from gas-powered boats segment: $182,000
  • Net loss from Forza X1 (electric boat entity): $2,005,000
  • Loss from Fix My Boat (franchise business): $5,000
  • Adjusted net loss (excluding non-cash charges): $1,347,000
  • Adjusted net income from gas-powered boats segment: $265,000

Twin Vee’s consolidated cash, cash equivalents, restricted cash, and marketable securities were $23,457,000 as of March 31, 2023. Forza X1 reported $10,683,000 in the same category, while Twin Vee’s core business had $12,643,000, and Fix My Boat had approximately $132,000.

We will closely monitor the performance of Forza X1, Inc. (Nasdaq: FRZA) in the coming weeks, considering that it is a spinoff from its parent company. It is crucial to conduct thorough research, particularly for companies like FRZA that have yet to achieve profitability. However, it is worth noting that the parent company has been making notable progress, as evidenced by its recent financial results, which revealed a substantial increase in the bottom line.

We will update you on FRZA when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

on

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Emerging Markets

Aemetis Inc. (NASDAQ: AMTX) Pioneers Renewable Fuel Market with EPA Approval

Published

on

Aemetis (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the EPA.

Aemetis, Inc. (NASDAQ: AMTX) shares surged 105% this week. The renewable natural gas and renewable fuels company received approval from the U.S. EPA to generate renewable identification numbers (RINs) under the federal Renewable Fuel Standard. They have six dairy biogas digesters up and running, with a seventh one scheduled to start operating in June 2023.

Aemetis plans to generate multiple sources of revenue from its renewable natural gas. They will sell the gas to replace petroleum diesel in transportation, sell California Low Carbon Fuel Standard credits to fuel blenders who need to meet carbon reduction requirements in California, sell the RINs generated under the federal Renewable Fuel Standard, and benefit from production tax credits starting in 2025 under the Inflation Reduction Act.

They have completed constructing and operating six dairy digesters, a biogas pipeline spanning over 40 miles, a central facility to upgrade biogas to renewable natural gas, and a utility pipeline interconnection unit. The renewable natural gas is injected into the utility gas system and stored underground until Aemetis Biogas obtains carbon intensity (CI) pathway approvals from the California Air Resources Board (CARB) to sell credits under the California Low Carbon Fuel Standard.

They have already completed 90 days of renewable natural gas production and data collection required for the CARB approval process. While the final pathway is under review by CARB, Aemetis can use a temporary CI pathway with a value of -150, allowing them to start generating revenue in the third quarter of 2023.

To Discover the Inside Scoop on AMTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Andy Foster, the president of Aemetis Biogas Inc., expressed excitement about the approval of Aemetis Biogas for generating D3 RINs, as it marks a significant milestone towards generating full product revenue. He emphasized that the company’s investments since 2019 have directly reduced greenhouse gas pollution, improved air quality in Central Valley communities, and created jobs. Aemetis is committed to expanding their network of dairy digesters and producing more carbon-negative renewable natural gas to replace petroleum diesel.

The dairy digesters, pipeline project, and biogas-to-RNG facility funding includes grants from the California Department of Food and Agriculture and the California Energy Commission. Aemetis also closed a $25 million long-term financing deal with Greater Commercial Lending last fall, supported by a loan guarantee from the USDA. This project financing has a low fixed interest rate for the first five years and spans over 20 years.

Aemetis has plans to file applications for an additional $100 million of loans from the USDA’s REAP loan program. These funds will support the engineering, permitting, and construction of 31 more dairies. Each loan application will be limited to a maximum of $25 million and carry a 20-year repayment term.

https://twitter.com/Theweedfarmer/status/1658946668052504576?s=20

Where could Aemetis, Inc. (NASDAQ: AMTX) be in 5 years?

The company has an ambitious Five Year Plan to generate substantial revenue and reduce air and carbon pollution. The plan projects $2.0 billion in revenues, $496 million in net income, and $682 million in adjusted EBITDA by 2027, with strong compound annual growth rates. Aemetis aims to expand its operations by producing Renewable Natural Gas (RNG), Sustainable Aviation Fuel (SAF), Renewable Diesel fuel (RD), and other low-carbon products. The plan emphasizes the positive financial impact of the Inflation Reduction Act.

The plan highlights the financial benefits of the Inflation Reduction Act, which enables the transfer of tax credits and incentives related to production, projected to improve net income by $341 million in 2027.

The plan also focuses on revenue growth in all product lines, including expanding the dairy RNG business, constructing a renewable jet/diesel plant, implementing carbon sequestration, and improving energy efficiencies. 

The company has already achieved significant milestones, such as completing biogas pipeline construction, upgrading facilities for biogas-to-RNG production, and progressing in carbon sequestration and renewable jet/diesel plant development. The company has also secured a biodiesel purchase agreement in India and made strides in constructing a solar microgrid and implementing energy-efficient measures.

We will update you on AMTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Leopold Böttcher from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.